Salveen Richter

Q: What is Salveen Richter's success rate?

Salveen Richter currently has a success rate of 81.20116773366149.

Q: What is the average return of Salveen Richter's calls?

Their stock ratings have generated an average return of 39.812155323372366.

Goldman Sachs | Healthcare

Salveen Richter is an analyst from Goldman Sachs specializing in the Healthcare sector. Ranked #626 out of 4650 analysts, they have issued 26 stock ratings with a success rate of 81.20% and an average return of 39.81%.

Salveen Richter has a well-established track record, with 26 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 81.20% and an average return of 39.81%, underscoring their expertise and ability to identify winning opportunities for investors.

#626

Out of 4650

Total Ratings

+81.20%

Success Rate

+39.81%

Average Return

Recent Ratings Analysis

ANNX

Hold

May 12, 2026

Target

$7.00

Current

$5.68

Performance

—

Salveen Richter rated ANNX as Neutral on May 12, 2026, setting a price target of 7. The Hold stance appears justified, as shares hovered around 5.68 with a % move.

BMRN

Hold

May 11, 2026

Target

$69.00

Current

$52.58

Performance

0.00%

On May 11, 2026, BMRN was given a Neutral rating by Salveen Richter, with a target price of 69. Market indecision, reflected in sideways trading near 52.58, supported the cautious call.

ELVN

Buy

May 08, 2026

Target

$59.00

Current

$39.59

Performance

-2.85%

ELVN received a Buy rating from Salveen Richter on May 08, 2026, aiming for 59. Price action was muted, as shares hovered around 39.59 despite the bullish outlook.

MRNA

Hold

May 04, 2026

Target

$49.00

Current

$52.88

Performance

11.80%

On May 04, 2026, Salveen Richter published a Neutral outlook on MRNA, with a target of 49. The Hold call missed some of the bullish momentum as shares advanced toward 49.

RLAY

Buy

Apr 28, 2026

Target

$22.00

Current

$12.85

Performance

-1.38%

Salveen Richter on Apr 28, 2026 assigned RLAY a Buy rating, with a price target of 22. The recommendation remains pending validation as shares consolidate around 12.85.

NTLA

Sell

Apr 28, 2026

Target

$9.00

Current

$14.42

Performance

9.24%

On Apr 28, 2026, Salveen Richter reaffirmed NTLA with a Sell rating, targeting 9. The Sell recommendation anticipated weakness, as shares dropped 9.24%.

QURE

Hold

Apr 20, 2026

Target

$10.00

Current

$27.64

Performance

53.22%

QURE was rated Neutral by Salveen Richter on Apr 20, 2026, with a price objective of 10. Despite caution, upside momentum rewarded risk-takers with gains to 27.64.

AGIO

Hold

Apr 01, 2026

Target

$32.00

Current

$27.99

Performance

-18.13%

On Apr 01, 2026, Salveen Richter initiated coverage on AGIO with a Neutral rating and target of 32. The rating matched the stock’s inability to hold above 27.99.

DNLI

Buy

Mar 26, 2026

Target

$40.00

Current

$19.67

Performance

—

Salveen Richter issued a Buy recommendation for DNLI on Mar 26, 2026, price target set at 40. The target of 40 remains in play, though confirmation will depend on future moves.

RARE

Hold

Mar 24, 2026

Target

$25.00

Current

$26.30

Performance

42.16%

On Mar 24, 2026, RARE was evaluated by Salveen Richter, who gave a Neutral rating and target of 25. Investors who stayed in despite the Hold saw upside of 42.16%.

GENB

Buy

Mar 24, 2026

Target

$26.00

Current

$14.37

Performance

19.45%

Salveen Richter rated GENB as Buy on Mar 24, 2026, setting a price target of 26. The call has proven timely, with shares rising 19.45% toward the price target of 26.

FOLD

Hold

Nov 05, 2025

Target

$11.00

Current

$14.49

Performance

57.67%

On Nov 05, 2025, FOLD was given a Neutral rating by Salveen Richter, with a target price of 11. The stock rallied from 14.49 to 14.49 after the Hold rating, surprising to the upside.

RCUS

Hold

Oct 30, 2025

Target

$16.00

Current

$24.86

Performance

23.13%

RCUS received a Neutral rating from Salveen Richter on Oct 30, 2025, aiming for 16. Investors saw gains of 23.13% that the cautious stance didn’t fully capture.

IONS

Hold

Sep 26, 2025

Target

$65.00

Current

$75.38

Performance

17.62%

On Sep 26, 2025, Salveen Richter published a Neutral outlook on IONS, with a target of 65. The Hold call missed some of the bullish momentum as shares advanced toward 65.

APLS

Sell

Sep 26, 2025

Target

$18.00

Current

$41.02

Performance

83.37%

Salveen Richter on Sep 26, 2025 assigned APLS a Sell rating, with a price target of 18. The market validated the bearish call with a pullback to 41.02.

IMNM

Buy

Sep 22, 2025

Target

$26.00

Current

$23.00

Performance

135.41%

On Sep 22, 2025, Salveen Richter reaffirmed IMNM with a Buy rating, targeting 26. The recommendation was supported by strong follow-through as the stock rose from 23 to 23.

ALNY

Buy

Sep 16, 2025

Target

$566.00

Current

$284.84

Performance

-38.24%

ALNY was rated Buy by Salveen Richter on Sep 16, 2025, with a price objective of 566. This case shows how bullish projections can fail, with the stock now below 284.84.

FDMT

Buy

Aug 12, 2025

Target

$38.00

Current

$10.79

Performance

75.45%

On Aug 12, 2025, Salveen Richter initiated coverage on FDMT with a Buy rating and target of 38. The stock’s climb of 75.45% since the call highlights the foresight in the rating.

ACAD

Sell

Aug 07, 2025

Target

$17.00

Current

$21.80

Performance

-10.66%

Salveen Richter issued a Sell recommendation for ACAD on Aug 07, 2025, price target set at 17. The Sell call exposed risks of betting against momentum, as the stock rallied -10.66%.

SRPT

Hold

Aug 07, 2025

Target

$19.00

Current

$19.40

Performance

8.02%

On Aug 07, 2025, SRPT was evaluated by Salveen Richter, who gave a Neutral rating and target of 19. Investors who stayed in despite the Hold saw upside of 8.02%.

ADPT

Buy

Mar 21, 2025

Target

$9.00

Current

$13.54

Performance

61.19%

Salveen Richter rated ADPT as Buy on Mar 21, 2025, setting a price target of 9. The call has proven timely, with shares rising 61.19% toward the price target of 9.

SMMT

Buy

Feb 28, 2025

Target

$42.00

Current

$18.66

Performance

-9.81%

On Feb 28, 2025, SMMT was given a Buy rating by Salveen Richter, with a target price of 42. Despite the Buy call, shares fell from 18.66 to 18.66, challenging the optimistic stance.

CRSP

Hold

Feb 13, 2025

Target

$57.00

Current

$54.01

Performance

24.19%

CRSP received a Neutral rating from Salveen Richter on Feb 13, 2025, aiming for 57. Investors saw gains of 24.19% that the cautious stance didn’t fully capture.

BIIB

Buy

Feb 13, 2025

Target

$245.00

Current

$197.95

Performance

42.98%

On Feb 13, 2025, Salveen Richter published a Buy outlook on BIIB, with a target of 245. Shares gained 42.98%, underscoring the accuracy of the bullish outlook toward 245.

GILD

Hold

Feb 12, 2025

Target

$96.00

Current

$133.52

Performance

29.24%

Salveen Richter on Feb 12, 2025 assigned GILD a Neutral rating, with a price target of 96. Shares outperformed expectations, climbing 29.24% despite the neutral view.

SAGE

Hold

Jul 26, 2024

Target

$11.00

Current

$8.68

Performance

-21.02%

On Jul 26, 2024, Salveen Richter reaffirmed SAGE with a Neutral rating, targeting 11. The Hold stance reflected market caution that was later justified.

Frequency Asked Questions

Who is Salveen Richter?

Salveen Richter is an analyst from Goldman Sachs specializing in the Healthcare sector.

What is Salveen Richter's success rate?

Salveen Richter currently has a success rate of +81.20%.

How many ratings has Salveen Richter issued?

Salveen Richter has issued 26 stock ratings so far.

What is the average return of Salveen Richter's calls?

Their stock ratings have generated an average return of +39.81%.

What is Salveen Richter's ranking?

Salveen Richter is ranked #626 out of 4650 analysts.

What types of ratings does Salveen Richter give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Salveen Richter?

You can follow Salveen Richter by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Salveen Richter?

Their latest rating was a Hold on ANNX issued on 2026-05-12.